Merck and Ridgeback’s molnupiravir offer hope to Covid-19 patients
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
Prostate cancer is the second-most common cancer in men and despite an increase in the number of available treatments for men with mCRPC, five-year survival remains low
Three new molecular diagnostic test panels for influenza and other common respiratory illnesses can be run together or alone using one patient sample
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
The company to receive upfront and milestone payments, in addition to royalties
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
Subscribe To Our Newsletter & Stay Updated